The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.
 
Jin Kang
No Relationships to Disclose
 
Xiang-Meng Li
No Relationships to Disclose
 
Jia-Tao Cheng
No Relationships to Disclose
 
Huajun Chen
No Relationships to Disclose
 
Xuchao Zhang
No Relationships to Disclose
 
Hai-Yan Tu
No Relationships to Disclose
 
Qing Zhou
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Jin-Ji Yang
No Relationships to Disclose